Hepatocellular carcinoma overview

Revision as of 21:45, 30 January 2018 by Dildar Hussain (talk | contribs)
Jump to navigation Jump to search
https://https://www.youtube.com/watch?v=zv04qtEM8qw%7C350}}

Hepatocellular carcinoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes of Hepatocellular carcinoma

Differentiating Hepatocellular carcinoma from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Diagnostic study of choice

History and symptoms

Physical Examination

Lab Tests

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hepatocellular carcinoma overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hepatocellular carcinoma overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hepatocellular carcinoma overview

CDC on Hepatocellular carcinoma overview

Hepatocellular carcinoma overview in the news

Blogs on Hepatocellular carcinoma overview

Directions to Hospitals Treating Hepatocellular carcinoma

Risk calculators and risk factors for Hepatocellular carcinoma overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]

Overview

Hepatocellular carcinoma (HCC, also called hepatoma) is a primary malignancy (cancer) of the liver. The majority of hepaticellular carcinoma cases are due to either a viral hepatitis infection (hepatitis B or C) or cirrhosis (alcoholism being the most common cause of hepatic cirrhosis).[1] In countries where hepatitis is not endemic, most malignant cancers in the liver are not primary hepatocellular carcinoma and the majority of cases are metastasis from other part of the body, e.g. the colon. Treatment options of hepatocellular carcinoma and prognosis are dependent on many factors, especially on tumor size and staging.

In non western countries, the usual outcome is poor, because only 10 - 20% of hepatocellular carcinomas can be removed completely using surgery. If the cancer cannot be completely removed, the disease is usually deadly within 3 to 6 months.[2] This is partially due to late presentation with large tumours, but also due to the lack of medical expertise and facilities. This is a rare tumor in the United States.

Historical Perspective

Hepatocellular carcinoma was first noted to be associated with hepatitis B infection in 1970.

Pathophysiology

On microscopic histopathological analysis, large polygonal tumours cells with graunular eosinophilic cytoplasm or layered dense collagen bundles are characteristic findings of hepatocellular carcinoma.

Causes

Common causes of hepatocellular carcinoma include hepatitis B, hepatitis C, alcoholic liver cirrhosis, hemochromatosis, and hepatic porphyrias.

Differentiating Hepatocellular Carcinoma from other Diseases

Hepatocellular carcinoma must be differentiated from other diseases that cause abdominal pain, jaundice, and weight loss, such as hepatitis B, hepatitis C, liver cirrhosis, and pancreatitis.

Epidemiology and Demographics

Hepatocellular carcinoma is the 5th most common tumor worldwide. The epidemiology of hepatocellular carcinoma exhibits two main patterns, one in North America and Western Europe and another in non-Western countries, such as those in Sub-Saharan Africa, Central Asia and Southeast Asia, and the Amazon basin. Men are more affected than women and it is more common between the 3rd and 5th decades of life. Hepatocellular carcinoma causes 662,000 deaths worldwide per year.[3]

Risk Factors

Common risk factors in the development of hepatocellular carcinoma are chronic hepatitis B, chronic hepatitis C, cirrhosis, and inherited metabolic diseases.

Screening

According to the American Association of Liver Diseases recommendations, screening for hepatocellular carcinoma by ultrasound (US) is recommended among patients with hepatitis B, hepatitis C, and cirrhosis. Screening is also recommended for Asian men over the age of 40, Asian women over the age of 50, and African American.

Natural History, Complications and Prognosis

The majority of hepatocellular carcinomas present with advanced disease because the symptoms tend to occur later in the course of the disease. Without treatment, the patient will develop symptoms of jaundice, ascites, right upper quadrant abdominal pain, nausea, and vomiting, which will eventually lead to death. There are a variety of complications associated with hepatocellular carcinoma such as jaundice, ascites, cachexia, and coagulopathy. Depending on the extent of the tumor at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor. If the cancer is inoperable, the disease is usually deadly within 3 to 6 months.

Diagnostic Studies

Staging

According to the TNM staging system, there are four stages of hepatocellular carcinoma based on the tumor size, lymph node involvement, and distant metastasis.

Diagnostic study of choice

Hepatocellular carcinoma is best diagnosed on a core biopsy of the liver. Core biopsy is done in a single visit at the hospital.

History and symptoms

The majority of patients with are asymptomatic hepatocellular carcinoma during the early stages of the disease. Symptoms of hepatocellular carcinoma include abdominal painnauseavomiting, weakness, jaundicepruritussplenomegalyfatiguehematemesisfever, and loss of appetite.

Physical examination

Patients with hepatocellular carcinoma usually appear cachectic. Physical examination of patients with hepatocellular carcinoma is usually remarkable for jaundicepruritusascitessplenomegalyesophageal varices, and cachexia.

Laboratory findings

An elevated concentration of serum alpha-fetoprotein (AFP) may be helpful in the diagnosis of hepatocellular carcinoma.

X-Ray

Performing chest x-ray might be helpful in detection of hepatocellular carcinoma metastasis to the lungs or to detect pleural effusion.

Abdominal CT

Abdominal CT scan with intravenous contrast agent is the best method to diagnose hepatocellular carcinoma.

Abdominal MRI

MRI may be helpful in the diagnosis of hepatocellular carcinoma.

Abdominal ultrasound

Ultrasound may be helpful in the diagnosis of hepatocellular carcinoma.

Other imaging studies

Portal vein angiography and hepatic artery angiography maybe helpful in the diagnosis of hepatocellular carcinoma.

Other diagnostic studies

Other diagnostic studies for hepatocellular carcinoma include laparoscopy and biopsy.

Treatment

Medical therapy

Patients with hepatocellular carcinoma are treated with ethanol injections, transcatheter arterial chemoembolization (TACE), sealed source radiotherapy, radiofrequency ablation (RFA), intra-arterial iodine-131-lipiodol administration, high intensity focused ultrasound (HIFU), hormonal therapy, and chemotherapy.

Surgery

The feasibility of surgery depends on the stage of hepatocellular carcinoma at time of diagnosis.

Primary prevention

Hepatitis B vaccine is recommended for all children to prevent the development of hepatitis B, which is a major risk factor for hepatocellular carcinoma. Other primary prevention strategies include abstinence from alcohol and screening for hemochromatosis.

References

  1. "Hepatocellular carcinoma".
  2. "Liver cancer - Hepatocellular carcinoma".
  3. "Hepatocellular carcinoma".


Template:WikiDoc Sources